ID   HEL
AC   CVCL_0001
SY   Hel; GM06141; GM06141B; Human ErythroLeukemia
DR   BTO; BTO:0000565
DR   CLO; CLO_0003679
DR   CLO; CLO_0023565
DR   EFO; EFO_0006579
DR   MCCL; MCC:0000187
DR   CLDB; cl0
DR   CLDB; cl1585
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   BioSample; SAMN03471056
DR   BioSample; SAMN03472269
DR   BioSample; SAMN10987697
DR   CCLE; HEL_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR   CCRID; 3131C0001000700071
DR   CCRID; 3142C0001000000070
DR   CCTCC; GDC0071
DR   Cell_Model_Passport; SIDM00594
DR   ChEMBL-Cells; CHEMBL3308090
DR   ChEMBL-Targets; CHEMBL613888
DR   Coriell; GM06141
DR   Cosmic; 787432
DR   Cosmic; 798663
DR   Cosmic; 850392
DR   Cosmic; 907053
DR   Cosmic; 919128
DR   Cosmic; 924040
DR   Cosmic; 947363
DR   Cosmic; 975251
DR   Cosmic; 976722
DR   Cosmic; 994176
DR   Cosmic; 996314
DR   Cosmic; 1012051
DR   Cosmic; 1013868
DR   Cosmic; 1037665
DR   Cosmic; 1070698
DR   Cosmic; 1078733
DR   Cosmic; 1122162
DR   Cosmic; 1127268
DR   Cosmic; 1139508
DR   Cosmic; 1139638
DR   Cosmic; 1140092
DR   Cosmic; 1151879
DR   Cosmic; 1168467
DR   Cosmic; 1170892
DR   Cosmic; 1171333
DR   Cosmic; 1176583
DR   Cosmic; 1191710
DR   Cosmic; 1192825
DR   Cosmic; 1601067
DR   Cosmic; 1604866
DR   Cosmic; 1633512
DR   Cosmic; 1943609
DR   Cosmic; 2089667
DR   Cosmic; 2131538
DR   Cosmic; 2306207
DR   Cosmic; 2649243
DR   Cosmic-CLP; 907053
DR   DepMap; ACH-000004
DR   DSMZ; ACC-11
DR   GDSC; 907053
DR   GEO; GSM482506
DR   GEO; GSM743410
DR   GEO; GSM887077
DR   GEO; GSM888147
DR   GEO; GSM1028243
DR   GEO; GSM1446763
DR   GEO; GSM1669874
DR   IARC_TP53; 21368
DR   JCRB; JCRB0062
DR   KCB; KCB 200808YJ
DR   LiGeA; CCLE_453
DR   LINCS_LDP; LCL-1053
DR   PharmacoDB; HEL_534_2019
DR   Wikidata; Q54882501
RX   CelloPub=CLPUB00447;
RX   DOI=10.1007/978-1-4757-1647-4_13;
RX   PubMed=6177045;
RX   PubMed=8558913;
RX   PubMed=9290701;
RX   PubMed=9510473;
RX   PubMed=9738977;
RX   PubMed=11021758;
RX   PubMed=14504097;
RX   PubMed=16408098;
RX   PubMed=20164919;
RX   PubMed=22460905;
RX   PubMed=23955599;
RX   PubMed=25485619;
RX   PubMed=27397505;
RX   PubMed=29533902;
RX   PubMed=30285677;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31160637;
RX   PubMed=31978347;
WW   http://www.proteinatlas.org/learn/cellines
WW   http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/h/cell-lines-detail-346.html
WW   http://www.cellresource.cn/fdetail.aspx?id=639
WW   http://www.cellresource.cn/fdetail.aspx?id=838
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Part of: LL-100 blood cancer cell line panel.
CC   Doubling time: ~24 hours (PubMed=6177045); ~36 hours (DSMZ).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Homozygous for JAK2 p.Val617Phe (c.1849G>T) (ClinVar=VCV000014662) (PubMed=16408098).
CC   Sequence variation: Homozygous for TP53 p.Met133Lys (c.398T>A) (CCLE; Cosmic-CLP).
CC   Omics: Deep antibody staining analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=2.4%; Native American=1.79%; East Asian, North=3.9%; East Asian, South=0%; South Asian=5.12%; European, North=13.33%; European, South=73.45% (PubMed=30894373).
CC   Miscellaneous: Originally the patient was suffering from Hodgkin lymphoma.
CC   Derived from sampling site: Peripheral blood.
ST   Source(s): CCRID; Cosmic-CLP; COG; DSMZ; JCRB; PubMed=25877200
ST   Amelogenin: X,Y (COG; PubMed=25877200)
ST   Amelogenin: X (CCRID; Cosmic-CLP; DSMZ; JCRB)
ST   CSF1PO: 10,11 (CCRID)
ST   CSF1PO: 10 (Cosmic-CLP; COG; DSMZ; JCRB; PubMed=25877200)
ST   D13S317: 9,11
ST   D16S539: 11
ST   D18S51: 12,16 (CCRID; PubMed=25877200)
ST   D18S51: 16 (COG)
ST   D19S433: 11,13
ST   D21S11: 29,30.2,31.2 (CCRID; COG)
ST   D21S11: 29,30.2 (PubMed=25877200)
ST   D2S1338: 18,19
ST   D3S1358: 15
ST   D5S818: 11
ST   D7S820: 7
ST   D8S1179: 13,15
ST   FGA: 21,22,23 (CCRID)
ST   FGA: 22,23 (COG; PubMed=25877200)
ST   Penta D: 11,13
ST   Penta E: 13,18
ST   TH01: 7
ST   TPOX: 11
ST   vWA: 14,17
DI   NCIt; C7152; Erythroleukemia
DI   ORDO; Orphanet_318; Acute erythroid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   30Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-07-20; Version: 33
//
RX   CelloPub=CLPUB00447;
RA   Mulivor R.A., Suchy S.F.;
RT   "1992/1993 catalog of cell lines. NIGMS human genetic mutant cell
RT   repository. 16th edition. October 1992.";
RL   (In) Institute for Medical Research (Camden, N.J.) NIH 92-2011; pp.1-918; National Institutes of Health; Bethesda (1992).
//
RX   DOI=10.1007/978-1-4757-1647-4_13;
RA   Biedler J.L.;
RT   "Chromosome abnormalities in human tumor cells in culture.";
RL   (In) Human tumor cells in vitro; Fogh J. (eds.); pp.359-394; Springer; New York (1975).
//
RX   PubMed=6177045; DOI=10.1126/science.6177045;
RA   Martin P., Papayannopoulou T.;
RT   "HEL cells: a new human erythroleukemia cell line with spontaneous and
RT   induced globin expression.";
RL   Science 216:1233-1235(1982).
//
RX   PubMed=8558913;
RA   Morita S., Tsuchiya S., Fujie H., Itano M., Ohashi Y., Minegishi M.,
RA   Imaizumi M., Endo M., Takano N., Konno T.;
RT   "Cell surface c-kit receptors in human leukemia cell lines and
RT   pediatric leukemia: selective preservation of c-kit expression on
RT   megakaryoblastic cell lines during adaptation to in vitro culture.";
RL   Leukemia 10:102-105(1996).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//
RX   PubMed=9510473; DOI=10.1111/j.1349-7006.1998.tb00476.x;
RA   Hosoya N., Hangaishi A., Ogawa S., Miyagawa K., Mitani K., Yazaki Y.,
RA   Hirai H.;
RT   "Frameshift mutations of the hMSH6 gene in human leukemia cell
RT   lines.";
RL   Jpn. J. Cancer Res. 89:33-39(1998).
//
RX   PubMed=9738977; DOI=10.1111/j.1349-7006.1998.tb03275.x;
RA   Takizawa J., Suzuki R., Kuroda H., Utsunomiya A., Kagami Y., Joh T.,
RA   Aizawa Y., Ueda R., Seto M.;
RT   "Expression of the TCL1 gene at 14q32 in B-cell malignancies but not
RT   in adult T-cell leukemia.";
RL   Jpn. J. Cancer Res. 89:712-718(1998).
//
RX   PubMed=11021758; DOI=10.1038/sj.leu.2401891;
RA   Majka M., Rozmyslowicz T., Honczarenko M., Ratajczak J., Wasik M.A.,
RA   Gaulton G.N., Ratajczak M.Z.;
RT   "Biological significance of the expression of HIV-related chemokine
RT   coreceptors (CCR5 and CXCR4) and their ligands by human hematopoietic
RT   cell lines.";
RL   Leukemia 14:1821-1832(2000).
//
RX   PubMed=14504097; DOI=10.1182/blood-2003-02-0418;
RA   Taketani T., Taki T., Sugita K., Furuichi Y., Ishii E., Hanada R.,
RA   Tsuchida M., Sugita K., Ida K., Hayashi Y.;
RT   "FLT3 mutations in the activation loop of tyrosine kinase domain are
RT   frequently found in infant ALL with MLL rearrangements and pediatric
RT   ALL with hyperdiploidy.";
RL   Blood 103:1085-1088(2004).
//
RX   PubMed=16408098; DOI=10.1038/sj.leu.2404081;
RA   Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.;
RT   "JAK2 V617F tyrosine kinase mutation in cell lines derived from
RT   myeloproliferative disorders.";
RL   Leukemia 20:471-476(2006).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23955599; DOI=10.1038/ng.2731;
RA   Kon A., Shih L.-Y., Minamino M., Sanada M., Shiraishi Y., Nagata Y.,
RA   Yoshida K., Okuno Y., Bando M., Nakato R., Ishikawa S.,
RA   Sato-Otsubo A., Nagae G., Nishimoto A., Haferlach C., Nowak D.,
RA   Sato Y., Alpermann T., Nagasaki M., Shimamura T., Tanaka H., Chiba K.,
RA   Yamamoto R., Yamaguchi T., Otsu M., Obara N., Sakata-Yanagimoto M.,
RA   Nakamaki T., Ishiyama K., Nolte F., Hofmann W.K., Miyawaki S.,
RA   Chiba S., Mori H., Nakauchi H., Koeffler H.P., Aburatani H.,
RA   Haferlach T., Shirahige K., Miyano S., Ogawa S.;
RT   "Recurrent mutations in multiple components of the cohesin complex in
RT   myeloid neoplasms.";
RL   Nat. Genet. 45:1232-1237(2013).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H.,
RA   Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y.,
RA   Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D.,
RA   Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D.,
RA   Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S.,
RA   Zhang Z.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=29533902; DOI=10.1515/hsz-2017-0321;
RA   Drexler H.G., Pommerenke C., Eberth S., Nagel S.;
RT   "Hodgkin lymphoma cell lines: to separate the wheat from the chaff.";
RL   Biol. Chem. 399:511-523(2018).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940-940(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E., Schweppe D.K.,
RA   Jedrychowski M., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//